| 摘要 |
A tumor-bearing mammal is treated by stimulating lymphocytes, including T lymphocyte subsets, in vitro in the presence of an antibody to a lymphocyte surface receptor for less than about 24 hours, optionally in the presence of IL-2, to form stimulated lymphocytes; infusing the stimulated lymphocytes into the tumor-bearing mammal; and administering one or more lymphokines to the mammal. The stimulated lymphocytes display enhanced immunotherapeutic activity, including increased cytotoxicity or lymphokine production in vivo, resulting in a decrease in the tumor burden by at least about 20 %. |
